
Immutep Ltd (IMMP) Stock Forecast & Price Target
Immutep Ltd (IMMP) Analyst Ratings
Bulls say
Immutep is a biotechnology company with a promising product pipeline and a strong financial position, making it a favorable investment opportunity. The clinical trials for its lead drug candidate efti have shown positive results in treating various types of cancer, and its unique mechanism of action sets it apart from other treatments. The company's experienced leadership and multiple ongoing studies add to its potential for success.
Bears say
Immutep is a late-stage clinical biotechnology company with a diversified product portfolio focused on developing novel immunotherapies for cancer and autoimmune diseases, using LAG-3's immune response capabilities. However, the company's potential success relies heavily on its lead product candidate, eftilagimod alfa (efti), which is currently in a registrational Phase 3 trial for first-line non-small cell lung cancer (NSCLC). Despite positive data in other indications, there are still unresolved questions about efti's efficacy and mechanism of action, as well as potential competition in the PD-L1-positive patient population. Moreover, the company's market potential in Europe may be limited by a relatively modest expected market penetration. Overall, the risks and uncertainties surrounding Immutep's main asset, combined with the competitive landscape and unproven success of its pipeline candidates, lead to a negative outlook on the company's stock.
This aggregate rating is based on analysts' research of Immutep Ltd and is not a guaranteed prediction by Public.com or investment advice.
Immutep Ltd (IMMP) Analyst Forecast & Price Prediction
Start investing in Immutep Ltd (IMMP)
Order type
Buy in
Order amount
Est. shares
0 shares